$0.25
-0.01 (-4.11%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AEON is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 2 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine PreventionNCT05016661Incidence of Treatment Emergent Adverse EventsRandomized · Triple-masked · Prevention | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to the analysis of the data not meeting the intended primary endpoint and key secondary endpoints. | Drug: ABP-450 | Migraine | 466 | 2024-07-31actual | 2024-09-20 |
| Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsNCT04845178Change in Monthly Migraine DaysRandomized · Triple-masked · Prevention | Phase 2 | Completed | Drug: ABP-450, Placebo | Migraine | 797 | 2024-06-19actual | 2024-09-04 |
| Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical DystoniaNCT04871451results2024-08-22Number of Participants With Treatment-related Serious Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABP-450 | Cervical Dystonia | 51 | 2023-07-24actual | 2024-08-22 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical DystoniaNCT04849988results2024-02-14Number of Participants With Treatment-Related Serious Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ABP-450, Placebo | Cervical Dystonia | 61 | 2022-07-11actual | 2024-02-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19